Deals Of The Week: Merck/Chimerix, Merck/Yamasa, CoDa/Rusnano/Domain
AstraZeneca has done a good job of preparing investors for revenue declines due to its patent cliff, but Wall Street thinks the pharma will need to undertake significant M&A activity to remain viable.
You may also be interested in...
Wound healing company CoDa Therapeutics is the first Domain portfolio company to benefit from the venture capital firm’s new, $760 million partnership with Russian sovereign fund Rusnano
The North Carolina-based start-up strikes a global deal for a Phase I HIV drug, which will allow it to fund late-stage trials on another lipid-antiviral conjugate.
New treatments for Type 2 diabetes are driving the optimism underlying Bristol and AstraZeneca’s proposed acquisition for Amylin and are leading to a re-alignment of allies and competitors focused on the disease. Companies are enthusiastic about the vast opportunity, yet worried about the costs and risks of full-scale commitment to it.